SCHEMBL1007576

SCHEMBL1007576

O=C(O)NC1c2ccccc2-c2ccccc21

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.62
KMT2A Q03164 2/20 0.61
MEN1 O00255 1/20 0.61
LMNA P02545 1/20 0.61
TSHR P16473 3/20 0.54
NPSR1 Q6W5P4 1/20 0.54
PPIA P62937 7/20 0.51
GAA P10253 1/20 0.51
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48
NCOR2 Q9Y618 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromomethane SCHEMBL5884083 0.94 KMT2A (0.61) MAPTKMT2AMEN1LMNATSHR
SCHEMBL29273709 0.84 MAPT (0.65) MAPTKMT2AMEN1LMNATSHR
SCHEMBL1567605 0.83 KMT2A (0.61) MAPTKMT2AMEN1LMNATSHR
SCHEMBL30735994 0.82 KMT2A (0.75) MAPTKMT2AMEN1LMNATSHR
SCHEMBL29124181 0.82 KMT2A (0.75) MAPTKMT2AMEN1LMNATSHR
SCHEMBL5525117 0.81 KMT2A (0.59) MAPTKMT2AMEN1LMNATSHR
SCHEMBL144326 0.81 KMT2A (0.65) MAPTKMT2AMEN1LMNATSHR
SCHEMBL16592358 0.79 CA12 (0.63) MAPTKMT2AMEN1TSHRPPIA
SCHEMBL367886 0.78 KMT2A (0.61) MAPTKMT2AMEN1LMNATSHR
SCHEMBL6290157 0.78 MAPT (0.67) MAPTKMT2AMEN1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112028801-B Chain extender and preparation method and application thereof 华南农业大学 2021-07-09 CN claimed
CN-112028801-A Chain extender and preparation method and application thereof 华南农业大学 2020-12-04 CN claimed
EP-2258951-B1 PHOTORESPONSIVE GAS-GENERATING MATERIAL, MICROPUMP AND MICROFLUID DEVICE SEKISUI CHEMICAL CO LTD (JP) 2018-08-22 EP claimed
CN-115916342-A Compounds, compositions and methods for treating fibrotic diseases and cancer 普渡研究基金会 2023-04-04 CN disclosed
CN-115427044-A Pyrrolopyrimidines as complement inhibitors 拜奥克里斯特制药公司 2022-12-02 CN disclosed
CN-114929675-A Novel adamantane derivatives as inhibitors of focal adhesion kinase 三进制药株式会社 2022-08-19 CN disclosed
CN-114751920-A Antitumor compounds 法马马有限公司 2022-07-15 CN disclosed
CN-114585370-A Oligonucleotide compositions and methods of use thereof 波涛生命科学有限公司 2022-06-03 CN disclosed
CN-114502177-A Oligonucleotide compositions and methods of use thereof 波涛生命科学有限公司 2022-05-13 CN disclosed
CN-110167915-B Amino-thiol compound, preparation method thereof and application thereof in radiation protection 上海科州药物研发有限公司 2021-11-26 CN disclosed
CN-113164761-A Modulators of alpha-1 antitrypsin 弗特克斯药品有限公司 2021-07-23 CN disclosed
US-7714162-B2 Base multiplying agents and base-reactive curable compositions SEKISUI CHEMICAL CO., LTD. (JP) 2010-05-11 US disclosed
US-20100099831-A1 Solid phase immobilized trifunctional linker SCHMIDT JURGEN G 2010-04-22 US disclosed
US-20080200580-A1 Base Multiplying Agents and Base-Reactive Curable Compositions SEKISUI CHEMICAL CO., LTD (JP) 2008-08-21 US disclosed
US-20070141724-A1 Solid phase immobilized trifunctional linker ENERGY, U.S. DEPARTMENT OF 2007-06-21 US disclosed
US-7041674-B2 Carbamic acid esters with anticholinergic activity BOEHRINGER INGELHIEM PHARMA GMBH & CO. KG (DE) 2006-05-09 US disclosed
US-20050027100-A1 Solid phase immobilized trifunctional linker LOS ALAMOS NATIONAL SECURITY, LLC 2005-02-03 US disclosed
US-20040132760-A1 Carbamic acid esters with anticholinergic activity BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-07-08 US disclosed
WO-2004011642-A1 GENERIC MEMBRANE ANCHORING SYSTEM THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2004-02-05 WO disclosed
US-6683201-B2 FOR THERAPY AND PROPHYLAXIS OF HYPERCHOLESTEROLEMIA, HYPERLIPEMIA, ARTERIOSCLEROSIS, VASCULAR DISEASES, MYCOSES, PARASITE INFECTIONS, GALLSTONES, TUMORS AND/OR HYPERPROLIFERATIVE DISORDERS, DIABETES HOFFMANN-LA ROCHE INC. 2004-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200580-A1 Base Multiplying Agents and Base-Reactive Curable Compositions RAD1, RAD51, REV1 MAPT 4250/4885KMT2A 1362/4885MEN1 89/4885
US-20040132760-A1 Carbamic acid esters with anticholinergic activity CHRM2, CHRM1, ACHE MAPT 1989/4885KMT2A 1182/4885MEN1 1418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.